A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Study sponsor: Ionis Pharmaceuticals, Inc. · IONS
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-08Estimated
Enrollment · participants151Actual
Source updated2025-12-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.